Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.
ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.
Report Urges Changes To Cut Activation Times For NCI Phase III Trials.
AACR Elects Officers.
Trending Stories
- “Father of tamoxifen” V. Craig Jordan dies at 76
- NCI faces prospect of an 11% cut in FY25—another setback in a period of tight budgets and sliding paylines
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Fred Hutch’s Christopher Li: Cancer centers should commit more resources to meet NCI’s Plan to Enhance Diversity requirements
- Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows